Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Organon & Co. before investing.

In this article, we go over a few key elements for understanding Organon & Co.’s stock price such as:

• Organon & Co.’s current stock price and volume
• Why Organon & Co.’s stock price changed recently
• Upgrades and downgrades for OGN from analysts
• OGN’s stock price momentum as measured by its relative strength

About Organon & Co. (OGN)

Before we jump into Organon & Co.’s stock price, history, target price and what caused it to recently , let’s take a look at some background.

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Want to learn more about Organon & Co.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Organon & Co..

Organon & Co.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Organon & Co.’s stock price was $13.550.

Organon & Co. is 0% from its previous closing price of $13.550.

During the last market session, Organon & Co.’s stock traded between $13.540 and $13.570. Currently, there are approximately 262.61 million shares outstanding for Organon & Co..

Organon & Co.’s price-earnings (P/E) ratio is currently at 17.1, which is low compared to the Pharmaceuticals industry median of 20.5. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Organon & Co. Stock Price History

Organon & Co.’s (OGN) price is currently up 0.07% so far this month.

During the month of July, Organon & Co.’s stock price has reached a high of $13.600 and a low of $13.460.

Over the last year, Organon & Co. has hit prices as high as $13.600 and as low as $5.690. Year to date, Organon & Co.’s stock is up 88.98%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Organon & Co. Stock’s Price to ?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of July 31, 2026,, no analysts have changed their rating of Organon & Co.’s stock over the last month.

Additionally, you'll want to evaluate Organon & Co.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Organon & Co.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Organon & Co.’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Organon & Co. (OGN) by visiting AAII Stock Evaluator.

Relative Price Strength of Organon & Co.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Organon & Co. has a weighted four-quarter relative price strength of 8.02%, which translates to a Momentum Score of 78 and is considered to be Strong.

Want to learn more about how Organon & Co. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Organon & Co. Stock Price: Bottom Line

As of July 31, 2026, Organon & Co.’s stock price is $13.550, which is 0% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Organon & Co. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.